Anti-fentanyl monoclonal antibody (CSX-1004 inferred)

About Cessation Therapeutics

Cessation Therapeutics is a private biotech focused on combating the fentanyl overdose epidemic with a first-in-class monoclonal antibody. Their mission is to provide durable protection against fentanyl and its analogs, potentially saving thousands of lives annually. The company has established research labs in San Diego and a corporate office in San Jose, advancing its lead candidate through preclinical and clinical development. With support from notable government and military figures, Cessation aims to deliver a critical public health solution to a national crisis.

Therapeutic Areas